Neurexophilin 4 Emerges as a Molecular Driver of Kidney Cancer Through PI3K/AKT-Controlled Glycolysis

Clear cell renal cell carcinoma, the most common and notoriously treatment-resistant form of kidney cancer, has long been recognized as a disease of metabolic sabotage. Its cells abandon the efficient energy-producing machinery that healthy cells rely on and instead ferment glucose at a frantic pace, a phenomenon known as aerobic glycolysis or the Warburg effect. Now, a team of researchers at Tangshan Workers’ Hospital in China has identified a surprising participant in this metabolic hijacking: neurexophilin 4, or NXPH4, a secreted protein previously linked to synapse formation and, more recently, to malignancy in several other cancers. According to the new study, NXPH4 acts as a molecular accelerator for the aggressive behavior of kidney cancer cells, driving their growth, invasion and migration by switching on the PI3K/AKT signaling pathway and thereby amplifying glycolysis.

The findings, published in the journal Molecular Genetics and Genomics, began with a bioinformatic sweep of publicly available cancer databases. The research team, led by Yan Liu and co-first authors Xiaolei Lv and Haitao Gao, found that NXPH4 was consistently and significantly overexpressed in clear cell renal cell carcinoma tissues compared with healthy kidney tissue. More ominously, elevated NXPH4 levels correlated with poor prognosis in patients with the disease, suggesting that the protein is not merely a passenger mutation but an active contributor to tumor progression. This pattern echoes previous reports linking NXPH4 to hepatocellular carcinoma, colorectal cancer, colon adenocarcinoma, bladder cancer, prostate cancer and breast cancer, but the new work is among the first to define its role in renal malignancy.

To move beyond correlation, the researchers performed a series of loss- and gain-of-function experiments in clear cell renal cell carcinoma cells grown in the laboratory. When they silenced NXPH4 using knockdown techniques, the cancer cells lost their predatory edge: viability dropped, invasion and migration slowed markedly, and apoptosis, the programmed cell death that cancer cells typically evade, increased. The opposite strategy, forcing NXPH4 overexpression, produced the mirror image of these effects. Cells became more viable, more invasive and more migratory, confirming that the protein functions as an oncogenic driver in this cancer type rather than a byproduct of tumor growth.

Because clear cell renal cell carcinoma is defined by its metabolic reprogramming, the team next turned to glycolysis. Database analysis revealed a positive correlation between NXPH4 expression and the levels of two canonical glycolytic enzymes: lactate dehydrogenase A, or LDHA, which converts pyruvate into lactate, and hexokinase 2, or HK2, which catalyzes the first committed step of glucose metabolism. When NXPH4 was suppressed in kidney cancer cells, protein levels of both LDHA and HK2 fell. When NXPH4 was elevated, glycolysis surged, as measured by glucose uptake, lactate production, ATP levels and the extracellular acidification rate, a standard readout of glycolytic flux. Oxygen consumption rates, which reflect mitochondrial respiration, rose in the knockdown experiments and fell with NXPH4 overexpression, indicating that the protein shifts the cell’s energy strategy away from oxidative phosphorylation and toward fermentative glycolysis.

The causal nature of this metabolic link was tested with a clever intervention. The researchers treated the cells with 2-deoxyglucose, a glucose analog that blocks glycolysis and is widely used in anti-glycolytic cancer research. Strikingly, 2-deoxyglucose reversed the pro-tumor effects of NXPH4, suppressing the viability, invasion and migration that the protein would otherwise promote. This experiment demonstrates that NXPH4’s oncogenic power in kidney cancer cells depends on the glycolytic engine it revs up; stall that engine, and the tumor-promoting signal loses much of its force.

The question then became how NXPH4 communicates with the glycolytic machinery. The answer, the researchers found, lies in the PI3K/AKT pathway, a signaling cascade whose dysregulation is a hallmark of clear cell renal cell carcinoma and a well-documented accomplice of the Warburg effect across many tumors. In the new study, raising NXPH4 levels activated PI3K/AKT signaling in the cancer cells. When the team pharmacologically blocked this pathway, the effect was dramatic: NXPH4-driven glycolysis, cell viability, invasion and migration were all significantly blunted. The evidence therefore sketches a coherent signaling chain in which NXPH4 acts upstream, AKT serves as the relay, and LDHA- and HK2-fueled glycolysis delivers the metabolic output that sustains malignancy.

These results add NXPH4 to a growing list of metabolic regulators implicated in renal cancer and place it within a broader literature connecting the PI3K/AKT axis to glucose metabolism in cancer. Recent work from other groups has shown that forkhead box protein K1 upregulates NXPH4 to promote proliferation, metastasis and glycolysis in colorectal cancer, and that NXPH4 enhances gemcitabine resistance in bladder cancer by modulating glycolysis through NDUFA4L2. In hepatocellular carcinoma, FOXK1-induced NXPH4 has similarly been linked to poor prognosis via the PI3K/Akt pathway. The consistency of this mechanism across tumor types suggests that NXPH4 may represent a class of secreted protein factors that couple growth signaling to metabolic rewiring, though the precise receptor interactions and upstream transcriptional control of NXPH4 in kidney tissue remain to be defined.

The clinical implications are potentially significant. Clear cell renal cell carcinoma accounts for the majority of kidney cancer deaths, and while immune checkpoint inhibitors and VHL/HIF-targeted therapies have improved outcomes in recent years, many patients eventually develop resistance. A glycolysis-centered dependency offers an alternative vulnerability: even if genetic drivers vary between patients, most clear cell tumors must maintain their glucose-hungry phenotype to survive. The new data indicate that suppressing NXPH4, either directly or by intercepting its activation of PI3K/AKT, could cripple this metabolic supply line. Combining such an approach with existing anti-glycolytic agents like 2-deoxyglucose derivatives, or with pathway inhibitors already approved for other cancers, could open new therapeutic avenues.

Cautious optimism is warranted. The study relies primarily on cell culture experiments and database correlations, and the authors note that all data generated during the work are available from the corresponding author upon request. Confirming the NXPH4-PI3K/AKT-glycolysis axis in animal models and, ultimately, in patient tumor samples will be essential before the protein can be pursued as a drug target or prognostic biomarker. Nevertheless, by tracing a single molecular thread from protein expression through signaling activation to metabolic reprogramming and malignant behavior, the Tangshan team has supplied a detailed mechanistic map of how kidney cancer feeds its own aggression. In a disease defined by metabolic flexibility, blocking the switch that keeps the sugar burning may prove to be a decisive blow.

Subject of Research: The role of neurexophilin 4 in clear cell renal cell carcinoma progression through PI3K/AKT-mediated glycolysis

Article Title: Neurexophilin 4 facilitates the malignant progression of kidney renal clear cell carcinoma by regulating PI3K/AKT-mediated glycolysis

Article References: Lv, X., Gao, H., Cui, D., Li, J., Li, X., & Liu, Y. (2026). Neurexophilin 4 facilitates the malignant progression of kidney renal clear cell carcinoma by regulating PI3K/AKT-mediated glycolysis. Molecular Genetics and Genomics, 301(1), Article 198. https://doi.org/10.1007/s00438-026-02483-3

Image Credits: AI Generated

DOI: 10.1007/s00438-026-02483-3

Keywords: clear cell renal cell carcinoma, NXPH4, glycolysis, PI3K/AKT pathway, LDHA, HK2, metabolic reprogramming, kidney cancer, cell invasion, apoptosis, 2-deoxyglucose, therapeutic target